Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
27
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Peters Malte | Director | 5 | $0 | $47.5K | 2025-08-19 |
| Coelho Mary Theresa | EVP and CFO | 4 | $0 | $12.5K | 2025-07-22 |
| Cassidy Sean A | Director | 1 | $0 | $0 | 2024-07-22 |
| Reilly Timothy P. | Director | 3 | $0 | $0 | 2024-06-17 |
| Kaufman David Ross | Director | 7 | $0 | $0 | 2024-06-17 |
| van de Winkel Jan | Director | 7 | $0 | $0 | 2024-06-17 |
| O'Neill Julie | Director | 8 | $0 | $0 | 2024-06-17 |
| Winderlich Mark | Chief Development Officer | 2 | $0 | $0 | 2024-04-15 |
| Necina Roman | Chief Technology Officer | 10 | $0 | $0 | 2024-04-15 |
| Orlinger Klaus | Sr. VP, Research | 23 | $0 | $197.4K | 2024-04-15 |
| Kandera Reinhard | Chief Financial Officer | 13 | $21.4K | $0 | 2024-04-15 |
| Aldag Jorn | Chief Executive Officer | 14 | $17.1K | $0 | 2024-04-15 |
| Schlienger Katia | Chief Medical Officer | 1 | $0 | $0 | 2023-04-14 |
| Baker Christine D. | Chief Operating Officer | 6 | $0 | $0 | 2023-04-14 |
| Kelly Michael Aaron | Director | 5 | $0 | $0 | 2022-06-30 |
| Matushansky Igor | Chief Medical Officer | 36 | $0 | $633.7K | 2022-06-30 |
| Soria Jean-Charles | Director | 2 | $0 | $0 | 2021-06-01 |
| Lengauer Christoph | Director | 5 | $0 | $0 | 2021-06-01 |
| Seghezzi Graziano | Director | 5 | $0 | $0 | 2021-06-01 |
| Sofinnova Partners SAS | 10% Owner | 8 | $0 | $8.41M | 2021-04-21 |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | 14 | $5.00M | $1.84M | 2021-03-29 |
| van Deventer Sander | Director | 4 | $0 | $0 | 2020-10-21 |
| Lilja Anders | Sr. VP, Technical Development | 7 | $0 | $146.5K | 2020-01-23 |
| Forbion Capital Fund II Cooperatief U.A. | 10% Owner | 7 | $750.0K | $0 | 2019-04-23 |
| Redmile Group, LLC | 10% Owner | 2 | $0 | $0 | 2019-04-23 |
| BAKER JULIAN | Other | 10 | $12.50M | $0 | 2019-04-23 |
| Pinschewer David | Chief Scientific Officer | 1 | $0 | $0 | 2019-04-17 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Peters Malte | Chief Executive Officer | S Sale | 2025-08-19 | 2025-10-09 | 25,172 | $0.82 | $20.6K | 54,347 | SEC↗ |
| Coelho Mary Theresa | EVP and CFO | S Sale | 2025-07-22 | 2025-07-23 | 13,609 | $0.92 | $12.5K | 56,266 | SEC↗ |
| Peters Malte | Chief Executive Officer | S Sale | 2025-07-22 | 2025-07-23 | 29,176 | $0.92 | $26.8K | 79,519 | SEC↗ |
| Cassidy Sean A | Director | A Award deriv | 2024-07-22 | 2024-07-24 | 9,800 | — | $0 | 9,800 | SEC↗ |
| Peters Malte | Chief Executive Officer | A Award | 2024-07-22 | 2024-07-24 | 108,695 | — | $0 | 108,695 | SEC↗ |
| Coelho Mary Theresa | EVP and CFO | A Award | 2024-07-22 | 2024-07-24 | 69,875 | — | $0 | 69,875 | SEC↗ |
| Reilly Timothy P. | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 49,000 | — | $0 | 49,000 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 49,000 | — | $0 | 49,000 | SEC↗ |
| Coelho Mary Theresa | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 49,000 | — | $0 | 49,000 | SEC↗ |
| Kaufman David Ross | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 49,000 | — | $0 | 49,000 | SEC↗ |
| Peters Malte | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 49,000 | — | $0 | 49,000 | SEC↗ |
| van de Winkel Jan | Director | A Award deriv | 2024-06-17 | 2024-06-18 | 98,000 | — | $0 | 98,000 | SEC↗ |
| Necina Roman | Chief Operations Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 367,300 | — | $0 | 367,300 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 971,400 | — | $0 | 971,400 | SEC↗ |
| Orlinger Klaus | Chief Scientific Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 367,300 | — | $0 | 367,300 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 406,200 | — | $0 | 406,200 | SEC↗ |
| Winderlich Mark | Chief Development Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Winderlich Mark | Chief Development Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | P Buy | 2023-08-21 | 2023-08-22 | 7,000 | $0.73 | $5.1K | 43,092 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | P Buy | 2023-08-16 | 2023-08-17 | 8,000 | $0.71 | $5.7K | 36,092 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | P Buy | 2023-07-11 | 2023-07-11 | 5,000 | $0.83 | $4.2K | 71,952 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | P Buy | 2023-07-07 | 2023-07-11 | 5,000 | $0.81 | $4.1K | 66,952 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | P Buy | 2023-07-05 | 2023-07-07 | 5,000 | $0.89 | $4.5K | 61,952 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | P Buy | 2023-07-03 | 2023-07-05 | 5,000 | $0.89 | $4.5K | 56,952 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | P Buy | 2023-06-30 | 2023-07-03 | 12,000 | $0.88 | $10.6K | 28,092 | SEC↗ |
| Coelho Mary Theresa | Director | A Award deriv | 2023-06-09 | 2023-06-09 | 52,000 | — | $0 | 52,000 | SEC↗ |
| Kaufman David Ross | Director | A Award deriv | 2023-06-09 | 2023-06-09 | 26,000 | — | $0 | 26,000 | SEC↗ |
| van de Winkel Jan | Director | A Award deriv | 2023-06-09 | 2023-06-09 | 52,000 | — | $0 | 52,000 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2023-06-09 | 2023-06-09 | 26,000 | — | $0 | 26,000 | SEC↗ |
| Reilly Timothy P. | Director | A Award deriv | 2023-06-09 | 2023-06-09 | 26,000 | — | $0 | 26,000 | SEC↗ |
| Peters Malte | Director | A Award deriv | 2023-06-09 | 2023-06-09 | 52,000 | — | $0 | 52,000 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2023-04-14 | 2023-04-18 | 513,600 | — | $0 | 513,600 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2023-04-14 | 2023-04-18 | 214,800 | — | $0 | 214,800 | SEC↗ |
| Baker Christine D. | Chief Operating Officer | A Award deriv | 2023-04-14 | 2023-04-18 | 275,800 | — | $0 | 275,800 | SEC↗ |
| Schlienger Katia | Chief Medical Officer | A Award deriv | 2023-04-14 | 2023-04-18 | 184,000 | — | $0 | 184,000 | SEC↗ |
| Necina Roman | Chief Development Officer | A Award deriv | 2023-04-14 | 2023-04-18 | 112,100 | — | $0 | 112,100 | SEC↗ |
| Orlinger Klaus | Chief Scientific Officer | A Award deriv | 2023-04-14 | 2023-04-18 | 194,200 | — | $0 | 194,200 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2022-06-30 | 2022-07-01 | 275,250 | — | $0 | 275,250 | SEC↗ |
| Baker Christine D. | Chief Operating Officer | A Award deriv | 2022-06-30 | 2022-07-01 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2022-06-30 | 2022-07-01 | 92,950 | — | $0 | 92,950 | SEC↗ |
| Kaufman David Ross | Director | A Award deriv | 2022-06-30 | 2022-07-01 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Kelly Michael Aaron | Director | A Award deriv | 2022-06-30 | 2022-07-01 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award deriv | 2022-06-30 | 2022-07-01 | 92,950 | — | $0 | 92,950 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award deriv | 2022-06-30 | 2022-07-01 | 48,350 | — | $0 | 48,350 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2022-06-30 | 2022-07-01 | 20,000 | — | $0 | 20,000 | SEC↗ |
| Orlinger Klaus | Chief Scientific Officer | A Award deriv | 2022-06-30 | 2022-07-01 | 48,350 | — | $0 | 48,350 | SEC↗ |
| Reilly Timothy P. | Director | A Award deriv | 2022-06-30 | 2022-07-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| van de Winkel Jan | Director | A Award deriv | 2022-06-30 | 2022-07-01 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2022-04-19 | 2022-04-20 | 275,250 | — | $0 | 275,250 | SEC↗ |
| Baker Christine D. | Chief Business Officer | A Award deriv | 2022-04-19 | 2022-04-20 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2022-04-19 | 2022-04-20 | 92,950 | — | $0 | 92,950 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award deriv | 2022-04-19 | 2022-04-20 | 92,950 | — | $0 | 92,950 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award deriv | 2022-04-19 | 2022-04-20 | 48,350 | — | $0 | 48,350 | SEC↗ |
| Orlinger Klaus | Chief Scientific Officer | A Award deriv | 2022-04-19 | 2022-04-20 | 48,350 | — | $0 | 48,350 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2022-02-01 | 2022-02-01 | 39,853 | $3.00 | $119.6K | 39,853 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2022-02-01 | 2022-02-01 | 23,427 | $3.00 | $70.3K | 23,427 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award deriv | 2022-02-01 | 2022-02-01 | 24,888 | $3.00 | $74.7K | 24,888 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award deriv | 2022-02-01 | 2022-02-01 | 21,486 | $3.00 | $64.5K | 21,486 | SEC↗ |
| Baker Christine D. | Chief Business Officer | A Award deriv | 2022-02-01 | 2022-02-01 | 22,763 | $3.00 | $68.3K | 22,763 | SEC↗ |
| Orlinger Klaus | Executive VP, Research | A Award deriv | 2022-02-01 | 2022-02-01 | 12,654 | $3.00 | $38.0K | 12,654 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award | 2022-02-01 | 2022-02-01 | 47,824 | $3.00 | $143.5K | 51,952 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award | 2022-02-01 | 2022-02-01 | 14,056 | $3.00 | $42.2K | 16,092 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award | 2022-02-01 | 2022-02-01 | 14,933 | $3.00 | $44.8K | 100,240 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award | 2022-02-01 | 2022-02-01 | 12,892 | $3.00 | $38.7K | 14,876 | SEC↗ |
| Baker Christine D. | Chief Business Officer | A Award | 2022-02-01 | 2022-02-01 | 13,658 | $3.00 | $41.0K | 16,158 | SEC↗ |
| Orlinger Klaus | Executive VP, Research | A Award | 2022-02-01 | 2022-02-01 | 9,188 | $3.00 | $27.6K | 10,404 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2021-12-21 | 2022-01-12 | 8,079 | — | $0 | 0 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2021-12-21 | 2022-01-12 | 11,366 | — | $0 | 2,842 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2021-12-21 | 2022-01-12 | 3,408 | — | $0 | 4,261 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2021-12-21 | 2022-01-12 | 2,205 | $2.49 | $5.5K | 85,307 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2021-12-21 | 2022-01-12 | 5,304 | $2.49 | $13.2K | 80,178 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2021-12-21 | 2022-01-12 | 11,366 | $0.10 | $1.1K | 91,544 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2021-12-21 | 2022-01-12 | 7,440 | $2.49 | $18.5K | 84,104 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2021-12-21 | 2022-01-12 | 3,408 | $0.10 | $341 | 87,512 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2021-12-21 | 2022-01-12 | 8,079 | $0.10 | $808 | 85,482 | SEC↗ |
| Kaufman David Ross | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Kelly Michael Aaron | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Lengauer Christoph | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 9,600 | — | $0 | 9,600 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Seghezzi Graziano | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Soria Jean-Charles | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 9,600 | — | $0 | 9,600 | SEC↗ |
| van de Winkel Jan | Director | A Award deriv | 2021-06-01 | 2021-06-04 | 19,200 | — | $0 | 19,200 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2021-04-21 | 2021-04-23 | 328,620 | $11.60 | $3.81M | 3,177,574 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2021-04-19 | 2021-04-21 | 207,600 | — | $0 | 207,600 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2021-04-19 | 2021-04-21 | 69,300 | — | $0 | 69,300 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award deriv | 2021-04-19 | 2021-04-21 | 95,250 | — | $0 | 95,250 | SEC↗ |
| Baker Christine D. | Chief Business Officer | A Award deriv | 2021-04-19 | 2021-04-21 | 49,950 | — | $0 | 49,950 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | A Award deriv | 2021-04-19 | 2021-04-21 | 26,050 | — | $0 | 26,050 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award deriv | 2021-04-19 | 2021-04-21 | 36,750 | — | $0 | 36,750 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2021-03-29 | 2021-03-31 | 36,829 | $13.67 | $503.5K | 3,506,194 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2021-03-26 | 2021-03-31 | 35,171 | $13.69 | $481.5K | 3,543,023 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2021-03-25 | 2021-03-29 | 28,546 | $13.12 | $374.5K | 3,578,194 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2021-03-24 | 2021-03-26 | 52,690 | $13.70 | $721.9K | 3,606,740 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2021-03-23 | 2021-03-25 | 40,000 | $13.91 | $556.4K | 3,659,430 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2021-03-22 | 2021-03-24 | 40,534 | $14.54 | $589.4K | 3,699,430 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2021-03-19 | 2021-03-23 | 166,230 | $14.60 | $2.43M | 3,739,964 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2020-12-17 | 2020-12-18 | 31,656 | — | $0 | 8,079 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2020-12-17 | 2020-12-18 | 5,965 | — | $0 | 7,669 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2020-12-17 | 2020-12-18 | 11,367 | — | $0 | 14,208 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2020-12-17 | 2020-12-18 | 29,628 | $0.10 | $3.0K | 93,881 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2020-12-17 | 2020-12-18 | 11,501 | $11.70 | $134.6K | 64,253 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2020-12-17 | 2020-12-18 | 16,478 | $11.76 | $193.8K | 77,403 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2020-12-17 | 2020-12-18 | 19,360 | $0.10 | $1.9K | 75,754 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2020-12-16 | 2020-12-18 | 640 | — | $0 | 39,735 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2020-12-16 | 2020-12-18 | 640 | $0.10 | $64 | 56,774 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2020-12-16 | 2020-12-18 | 380 | $11.70 | $4.4K | 56,394 | SEC↗ |
| Soria Jean-Charles | Director | A Award deriv | 2020-12-15 | 2020-12-17 | 19,200 | — | $0 | 19,200 | SEC↗ |
| van de Winkel Jan | Director | A Award | 2020-10-21 | 2020-10-23 | 9,153 | — | $0 | 9,153 | SEC↗ |
| Kelly Michael Aaron | Director | A Award | 2020-10-21 | 2020-10-23 | 5,754 | — | $0 | 5,754 | SEC↗ |
| Kaufman David Ross | Director | A Award | 2020-10-21 | 2020-10-23 | 4,577 | — | $0 | 4,577 | SEC↗ |
| Lengauer Christoph | Director | A Award | 2020-10-21 | 2020-10-23 | 4,603 | — | $0 | 4,603 | SEC↗ |
| O'Neill Julie | Director | A Award | 2020-10-21 | 2020-10-23 | 4,969 | — | $0 | 4,969 | SEC↗ |
| van Deventer Sander | Director | A Award | 2020-10-21 | 2020-10-23 | 2,485 | — | $0 | 2,485 | SEC↗ |
| Seghezzi Graziano | Director | A Award | 2020-10-21 | 2020-10-23 | 4,708 | — | $0 | 4,708 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2020-10-02 | 2020-10-06 | 300 | $10.00 | $3.0K | 3,906,194 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2020-09-15 | 2020-09-17 | 32,336 | $12.45 | $402.6K | 3,915,755 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2020-09-15 | 2020-09-17 | 9,261 | $13.16 | $121.9K | 3,906,494 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award | 2020-07-20 | 2020-07-22 | 4,128 | — | $0 | 4,128 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award | 2020-07-20 | 2020-07-22 | 2,736 | — | $0 | 56,134 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award | 2020-07-20 | 2020-07-22 | 2,036 | — | $0 | 2,036 | SEC↗ |
| Orlinger Klaus | EVP, Research | A Award | 2020-07-20 | 2020-07-22 | 1,216 | — | $0 | 1,216 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award | 2020-07-20 | 2020-07-22 | 1,984 | — | $0 | 1,984 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2020-07-20 | 2020-07-22 | 12,483 | $11.94 | $149.0K | 3,948,091 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2020-06-29 | 2020-07-01 | 3,280 | $11.78 | $38.6K | 3,960,574 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | S Sale | 2020-06-29 | 2020-07-22 | 3,280 | $11.78 | $38.6K | 3,960,574 | SEC↗ |
| Sofinnova Partners SAS | 10% Owner | S Sale | 2020-06-29 | 2020-07-24 | 3,280 | $11.78 | $38.6K | 3,960,574 | SEC↗ |
| Seghezzi Graziano | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 9,600 | — | $0 | 9,600 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Lengauer Christoph | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 9,600 | — | $0 | 9,600 | SEC↗ |
| van de Winkel Jan | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 19,200 | — | $0 | 19,200 | SEC↗ |
| Kelly Michael Aaron | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Kaufman David Ross | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 9,600 | — | $0 | 9,600 | SEC↗ |
| van Deventer Sander | Director | A Award deriv | 2020-06-18 | 2020-06-19 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2020-04-20 | 2020-04-24 | 77,400 | — | $0 | 0 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2020-04-20 | 2020-04-24 | 200,000 | — | $0 | 0 | SEC↗ |
| Orlinger Klaus | EVP, Research | A Award deriv | 2020-04-20 | 2020-04-24 | 30,000 | — | $0 | 0 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award deriv | 2020-04-20 | 2020-04-24 | 50,000 | — | $0 | 0 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award deriv | 2020-04-20 | 2020-04-24 | 65,200 | — | $0 | 0 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2020-01-29 | 2020-01-31 | 5,500 | $12.73 | $70.0K | 53,398 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | M Exercise deriv | 2020-01-23 | 2020-01-27 | 7,568 | — | $0 | 13,098 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | M Exercise deriv | 2020-01-23 | 2020-01-27 | 4,075 | — | $0 | 0 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | S Sale | 2020-01-23 | 2020-01-27 | 7,568 | $12.81 | $96.9K | 0 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | M Exercise | 2020-01-23 | 2020-01-27 | 4,075 | $0.10 | $408 | 4,075 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | S Sale | 2020-01-23 | 2020-01-27 | 4,075 | $12.17 | $49.6K | 0 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | M Exercise | 2020-01-23 | 2020-01-27 | 7,568 | $0.10 | $757 | 7,568 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise deriv | 2020-01-21 | 2020-01-21 | 6,789 | — | $0 | 7,741 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise | 2020-01-21 | 2020-01-21 | 6,789 | $0.10 | $679 | 6,789 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | S Sale | 2020-01-21 | 2020-01-21 | 6,789 | $12.02 | $81.6K | 0 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise deriv | 2020-01-16 | 2020-01-21 | 1,140 | — | $0 | 0 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise deriv | 2020-01-16 | 2020-01-21 | 571 | — | $0 | 14,530 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | S Sale | 2020-01-16 | 2020-01-21 | 1,711 | $11.56 | $19.8K | 0 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise | 2020-01-16 | 2020-01-21 | 571 | $0.10 | $57 | 1,711 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise | 2020-01-16 | 2020-01-21 | 1,140 | $0.10 | $114 | 1,140 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise deriv | 2020-01-14 | 2020-01-16 | 1,142 | — | $0 | 1,140 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise deriv | 2020-01-14 | 2020-01-16 | 7,358 | — | $0 | 0 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | S Sale | 2020-01-14 | 2020-01-16 | 8,500 | $11.30 | $96.0K | 0 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise | 2020-01-14 | 2020-01-16 | 1,142 | $0.10 | $114 | 8,500 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | M Exercise | 2020-01-14 | 2020-01-16 | 7,358 | $0.10 | $736 | 7,358 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2019-12-19 | 2019-12-23 | 6,000 | $0.10 | $600 | 40,375 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2019-12-19 | 2019-12-23 | 19,891 | $0.10 | $2.0K | 25,575 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2019-12-19 | 2019-12-23 | 6,000 | $0.10 | $600 | 49,411 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2019-12-19 | 2019-12-23 | 10,404 | $9.93 | $103.3K | 58,898 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2019-12-19 | 2019-12-23 | 19,891 | $0.10 | $2.0K | 69,302 | SEC↗ |
| van Deventer Sander | Director | A Award deriv | 2019-12-18 | 2020-01-03 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Seghezzi Graziano | Director | A Award deriv | 2019-12-18 | 2020-01-03 | 9,600 | — | $0 | 9,600 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2019-12-18 | 2020-01-03 | 9,600 | — | $0 | 9,600 | SEC↗ |
| Lengauer Christoph | Director | A Award deriv | 2019-12-18 | 2020-01-03 | 9,600 | — | $0 | 9,600 | SEC↗ |
| van de Winkel Jan | Director | A Award deriv | 2019-12-18 | 2020-01-03 | 28,800 | — | $0 | 28,800 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise deriv | 2019-12-17 | 2019-12-19 | 26,312 | $0.10 | $2.6K | 46,375 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | M Exercise | 2019-12-17 | 2019-12-19 | 26,312 | $0.10 | $2.6K | 54,895 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | S Sale | 2019-12-17 | 2019-12-19 | 11,484 | $7.87 | $90.4K | 43,411 | SEC↗ |
| Necina Roman | Chief Technology Officer | A Award deriv | 2019-12-09 | 2019-12-11 | 125,008 | — | $0 | 125,008 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 60,194 | — | $0 | 0 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 60,194 | — | $0 | 60,194 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 324,421 | — | $0 | 0 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 2,905,359 | — | $0 | 2,905,359 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 2,905,359 | — | $0 | 0 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 324,421 | — | $0 | 324,421 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 529,758 | — | $0 | 529,758 | SEC↗ |
| BAKER JULIAN | Other | C Conversion deriv | 2019-04-23 | 2019-04-23 | 529,758 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-24 | 85,830 | — | $0 | 0 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-25 | 888,166 | — | $0 | 0 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-25 | 1,719,189 | — | $0 | 0 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-25 | 916,901 | — | $0 | 0 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-25 | 687,673 | — | $0 | 0 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-25 | 597,497 | — | $0 | 0 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | C Conversion deriv | 2019-04-23 | 2019-04-25 | 1,146,118 | — | $0 | 0 | SEC↗ |
| BAKER JULIAN | Other | P Buy | 2019-04-23 | 2019-04-23 | 72,128 | $14.00 | $1.01M | 72,128 | SEC↗ |
| BAKER JULIAN | Other | P Buy | 2019-04-23 | 2019-04-23 | 820,729 | $14.00 | $11.49M | 820,729 | SEC↗ |
| Redmile Group, LLC | 10% Owner | C Conversion | 2019-04-23 | 2019-04-24 | 999,322 | — | $0 | 999,322 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | C Conversion | 2019-04-23 | 2019-04-25 | 916,901 | — | $0 | 999,357 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | C Conversion | 2019-04-23 | 2019-04-25 | 888,166 | — | $0 | 3,606,712 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | P Buy | 2019-04-23 | 2019-04-25 | 357,142 | $14.00 | $5.00M | 3,963,854 | SEC↗ |
| SOFINNOVA CAPITAL VI FCPR | 10% Owner | C Conversion | 2019-04-23 | 2019-04-25 | 1,719,189 | — | $0 | 2,718,546 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | C Conversion | 2019-04-23 | 2019-04-25 | 1,146,118 | — | $0 | 1,843,105 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | C Conversion | 2019-04-23 | 2019-04-25 | 597,497 | — | $0 | 2,440,602 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | P Buy | 2019-04-23 | 2019-04-25 | 53,571 | $14.00 | $750.0K | 2,494,173 | SEC↗ |
| Forbion Capital Fund II Cooper | 10% Owner | C Conversion | 2019-04-23 | 2019-04-25 | 687,673 | — | $0 | 696,987 | SEC↗ |
| van Deventer Sander | Director | A Award deriv | 2019-04-17 | 2019-04-24 | 19,200 | — | $0 | 19,200 | SEC↗ |
| Lilja Anders | Sr. VP, Technical Developmen | A Award deriv | 2019-04-17 | 2019-04-24 | 42,784 | — | $0 | 42,784 | SEC↗ |
| Seghezzi Graziano | Director | A Award deriv | 2019-04-17 | 2019-04-24 | 19,200 | — | $0 | 19,200 | SEC↗ |
| Aldag Jorn | Chief Executive Officer | A Award deriv | 2019-04-17 | 2019-04-24 | 604,656 | — | $0 | 604,656 | SEC↗ |
| Kaufman David Ross | Director | A Award deriv | 2019-04-17 | 2019-04-24 | 19,200 | — | $0 | 19,200 | SEC↗ |
| Kelly Michael Aaron | Director | A Award deriv | 2019-04-17 | 2019-04-24 | 19,200 | — | $0 | 19,200 | SEC↗ |
| Orlinger Klaus | Sr. VP, Research | A Award deriv | 2019-04-17 | 2019-04-24 | 42,784 | — | $0 | 42,784 | SEC↗ |
| O'Neill Julie | Director | A Award deriv | 2019-04-17 | 2019-04-24 | 6,924 | — | $0 | 6,924 | SEC↗ |
| Kandera Reinhard | Chief Financial Officer | A Award deriv | 2019-04-17 | 2019-04-24 | 87,648 | — | $0 | 87,648 | SEC↗ |
| Lengauer Christoph | Director | A Award deriv | 2019-04-17 | 2019-04-24 | 6,924 | — | $0 | 6,924 | SEC↗ |
| Pinschewer David | Chief Scientific Officer | A Award deriv | 2019-04-17 | 2019-04-24 | 116,416 | — | $0 | 116,416 | SEC↗ |
| Matushansky Igor | Chief Medical Officer | A Award deriv | 2019-04-17 | 2019-04-24 | 52,064 | — | $0 | 52,064 | SEC↗ |